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Epidemiology
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1996: Vaccine recommended 
31,032 cases, Rate = 11.7/100,000
1971: 59,606 cases, Rate = 28.9/100,000
2011: 1,398 cases, 
Rate = 0.4/100,000
1996-2011: 95.5% decrease in reported cases
2017: 3,365
Rate = 1.0/100,000
Rates of Reported Acute Hepatitis A Cases ── United 
States, 1966-2017
CDC, National Notifiable Diseases Surveillance System (NNDSS); Armstrong GL. Pediatrics 2007;119:e22-9 44
Rates of Reported Acute Hepatitis A Cases —
United States, 2000-2017
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Source: CDC, National Notifiable Diseases Surveillance System;   Pre-Decisional: for federal use only; not for distribution.
Rates of Reported Acute Hepatitis A, by Age Group —
United States, 2002-2017
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6Source: CDC, National Notifiable Diseases Surveillance System. Pre-Decisional; for federal use only; not for distribution.
Widespread Outbreaks of Hepatitis A across the United States: 2016-Present
7https://www.cdc.gov/hepatitis/outbreaks/2017March-HepatitisA.htm
Data Sources: National Notifiable Diseases Surveillance (NNDSS), US Census Bureau
Hepatitis A Incidence – United States
Hepatitis A incidence rate 
per 100,000 population
2018*2015
*2018 Data are preliminary
8
Reported Incident Hepatitis A Cases by MMWR Week, NND
United States, 2017─Present
SS —
Data are provisional -- Not for Distribution(LIGHT PINK BARS IN THIS AND SUBSEQUENT FIGURES INDICATES 7-WEEK PERIOD OF POTENTIAL SURVEILLANCE REPORTING LAG) 9
Epidemiology of Hepatitis A Infections 
 Asymptomatic children were associated with HAV transmission in past outbreaks
 Recent outbreaks now primarily affect adults, causing severe disease
–
–
–
Hepatitis B, hepatitis C co-infection
Many cases among persons who use drugs or persons experiencing homelessness
• Person-to-person contact
– Crowding, poor hygiene
• Estimated tens of millions of dollars in healthcare costs
Men who have sex with men (MSM)
 Person-to-person spread is now the predominant mode of HAV transmission
 Sporadic foodborne outbreaks continue to occur
10
Hepatitis A Vaccines
11
Vaccines Used to Prevent Hepatitis A Virus (HAV) Infection
12
Vaccine
Trade name 
(manufacturer) Age (yrs) Dosage Route Schedule Booster
Hepatitis A 
vaccine, 
inactivated
HAVRIX 
(GlaxoSmithKline)
1–18 0.5 mL (720 ELU) IM 0, 6–12 mo None
≥19 1 mL (1,440 ELU) IM 0, 6–12 mo None
Hepatitis A 
vaccine, 
inactivated
VAQTA
(Merck & Co., Inc.)
1–18 0.5 mL (25 U) IM 0, 6–18 mo None
≥19 1 mL (50 U) IM 0, 6–18 mo None
Combined 
hepatitis A -
hepatitis B 
vaccine
TWINRIX 
(GlaxoSmithKline)
≥18 (primary) 1 mL (720 ELU HAV + 20 µg 
HBsAg)
IM 0, 1, 6 mo None
≥18 (accelerated) 1 mL (720 ELU HAV + 20 µg 
HBsAg)
IM 0, 7, 21–30 d 12 mo
Abbreviations: ELU = ELISA units of inactivated HAV; HBsAg = hepatitis B surface antigen; IM = intramuscular; U = units of HAV antigen.
Hepatitis A Vaccines in 1995 and 1996 
Efficacy of Hepatitis A Vaccines* 
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Vaccine* Site andAge Group
Number in 
Trial
Vaccine Efficacy
(95 % Cl)
VAQTA®, Merck, Sharpe, 
and Dohme
(MSD)1
New York
2-16 years 1,037 100% (85-100%)
§
HAVRIX®, SmithKline 
Beecham
(SKB)2
Thailand
1-16 years 38,157 94% (74-98%)
*Pediatric formulation                         
˝ Determined 6–18 months after dose 1
(1) Werzberger, A et al. New Engl J Medicine. 1992;327:453–7 
(2) Innis BL, et al. JAMA 1994;271:1328–34
Immunogenicity of Hepatitis A Vaccines 
 All licensed vaccines are highly immunogenic when administered to children and 
adolescents according to multiple schedules
–
–
–
–
97%–100% of persons aged 2–18 years had protective levels of antibody 1 month after receiving 
the first dose
100% had protective levels 1 month after the second dose, with high geometric mean titers 
(GMTs) 
 All licensed vaccines are highly immunogenic in persons aged >18 years when 
administered according to the recommended schedules 
Protective antibody levels were identified in 94%–100% of immunocompetent adults one month 
after the first dose
After the second dose, all persons had protective levels of antibody, with high GMTs
14
Clemens R et al. J Infect Dis 1995;171(Suppl 1):S44–9.                  Nalin DR. VAQTA™; Drugs of the Future 1995;20:24–9.
McMahon BJ, et al. J Infect Dis 1995;171:676–9.                             Sharapov et al. Hepatology, 2012; 56: 516–522.
Van Herck et al. Expert Review of Vaccines 2005; 4(4): 459-471.
Immunogenicity – Long-term Protection
 Anti-HAV has been shown to persist in vaccine recipients for at least 
22 years in adults administered inactivated vaccine as children with a 
three-dose schedule1
 At least 20 year anti-HAV persistence was demonstrated among adults 
vaccinated with a two-dose schedule as adults2
 Detectable antibodies are estimated to persist for 40 years or longer 
based on mathematical modeling and anti-HAV kinetic studies2,3
 Protection following natural infection is lifelong and may also be 
following vaccination
1. Mosites, E, et al. J Med Virol. 2018; 90: 1418– 1422.; 2. Theeten H, et al. Vaccine. 2015 Oct 13;33(42):5723-7. 
3. Hens N, et al. Vaccine. 2014;32(13):1507-1513. 
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Hepatitis A Vaccine Safety
 In pre-licensure trials, adverse reactions to HAVRIX, VAQTA and TWINRIX were
mostly injection site reactions and mild systemic reactions
 Postmarketing surveillance for adverse events following receipt of HepA vaccines
performed primarily by two systems in the U.S.: the Vaccine Adverse Event
Reporting System (VAERS) and the Vaccine Safety Datalink (VSD)
– No unusual or unexpected safety patterns observed for any HepA vaccines licensed in the U.S.
Vaccine Information Statement (VIS) https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-a.html
MMWR 2006;55(RR-7)
Unpublished CDC 16
ACIP Hepatitis A Vaccine Recommendations
 Targeted vaccination, 1996-1999 
–
–
1996 
• Children at age 2 years in communities with high rates of disease
• Children at age 2 years and older children in outbreaks 
1999 
• Recommended in 11 states with rates 2x the national average
• Considered in 6 states with rates above the national average 
 Routine vaccination, 2006
• Universal early childhood vaccination
– Recommended for use at age 12-23 months in all states 
• Continue existing vaccination programs for ages 2-18 years
• Consider catch-up vaccination in outbreaks and areas 
with increasing disease rates     
• Any person wishing to obtain immunity
17MMWR 1996;45(RR-15); MMWR 1999;48(RR-12); MMWR 2006;55(RR-7)
ACIP Hepatitis A Vaccine Recommendations
Groups at increased risk of HAV or severe HAV disease
 Persons traveling 
 Men who have sex with men
 Persons who use injection and non-injection drugs
 Persons with clotting-factor disorders
 Persons with occupational risk for infection
 Persons who anticipate close personal contact with an international adoptee 
 Persons experiencing homelessness
 Persons with chronic liver disease 
 Persons with HIV
MMWR 1996;45(RR-15); MMWR 1999;48(RR-12); MMWR 2006;55(RR-7) 18
Hepatitis A Vaccine Coverage, United States, 2017
 Children1
–
–
–
–
–
–
–
59.7% for children age 19-35 months, ≥2 doses 
86.0% for children age 19-35 months, ≥1 dose
 Adolescents2 
68.4% for adolescents age 13-17 years, ≥2 doses
77.2% for adolescents age 13-17 years, 1 dose
 Adults3
10.9% for adults ≥19 years, ≥2 doses; Travelers, 17.7%; Chronic liver disease, 20.8%
15.7% for adults 19-49 years, ≥2 doses; Travelers, 22.2%; Chronic liver disease, 25.1% 
6.1% for adults ≥50 years, ≥2 doses
19
1. Hill HA, et al. MMWR 2018;66:1171–1177. 
2. Unpublished data from Assessment Branch/ISD/NCIRD/CDC – Not for Distribution
3. Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2017.
https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html#box2
Estimated Vaccination Coverage with Selected Vaccines and Doses*
among Adolescents Aged 13-17 Years, by Survey Year — National 
Immunization Survey-Teen, United States, 2008-2017†
20Includes unpublished data from Assessment Branch/ISD/NCIRD/CDC – Not for Distribution
Abbreviations: 
Tdap = tetanus toxoid, reduced 
diphtheria toxoid, and acellular 
pertussis vaccine; 
MenACWY = quadrivalent
meningococcal conjugate vaccine; 
HPV = human papillomavirus; APD 
= adequate provider data.
State Requirements for Hepatitis A Vaccine 
21
Immunization Action Coalition
http://www.immunize.org/pdfs/hepa.pdf
Catch-up Hepatitis A Vaccination
22
Proposed Routine Recommendations for Children
 ACIP recommends hepatitis A vaccination for all children aged 12-
23 months [Current]
 ACIP recommends that all children and adolescents aged 2 
through 18 years who have not previously received hepatitis A 
vaccine be vaccinated at any age (i.e., children and adolescents 
are recommended for catch-up vaccination) [Proposed] 
23
Policy question:
Should hepatitis A catch-up vaccination be recommended for 
children aged 2-18 years?
24
Population Children aged 2-18 years
Intervention Hepatitis A vaccination (HepA vaccine series)
Comparison Hepatitis A vaccination based on clinical decision making
Outcomes of 
interest
• Hepatitis A infection
• Adverse events
WORK GROUP JUDGEMENTS
             | No  Probably No Uncertain  Probably Yes Yes Varies
EVIDENCE
– Incidence: The rate of reported acute hepatitis A cases in 2017 was 1.0 case/100,000 population
(Unpublished, CDC)
• 1.45 cases/100,000 population among young adults aged 20-30 years (unpublished, CDC)
–
–
–
–
0.87 cases/ 100,000 population in 2016 (NNDSS)
• 2.07 cases/100,000 population among adults aged 30-39 years (unpublished, CDC)
0.92 cases/ 100,000 population in 2016 (NNDSS)
Highest rate and more than double the 2016 rate for this age group
HepA vaccine coverage: In 2017, national hepatitis A vaccine ≥2 dose coverage was 68.4% for
adolescents age 13-17 years; 1 dose coverage was 77.2% (Unpublished, CDC)
• Among adolescents age 13-17 living in states where routine vaccination at 12-23 months was first
recommended in 2006, coverage is only slightly lower than the total cohort, 61% for ≥2 doses and
71% with ≥ 1 dose, despite catch-up vaccination being based on shared clinical decision making. 
25
Criteria 1: Is the problem of public health importance?
WORK GROUP JUDGEMENTS
                | 
–
–
No Probably No Uncertain Probably Yes  Yes Varies
Additional Information
HAV outbreaks: Since the outbreaks were first identified in 2016, as of June 21, 2019, 24 states have 
publicly reported the following: Cases: 20,512; Hospitalizations: 11,776 (57%); Deaths: 194
https://www.cdc.gov/hepatitis/outbreaks/2017March-HepatitisA.htm
• Among states with publically available case information by age group, the median age of HAV cases is 
in the 30s, with a substantial percentage of cases aged in their 20s and 40s
HepA vaccine coverage: 
• Vaccinating adolescents who could be at risk for HAV infection at present or in the future (e.g., 
persons who use drugs, persons experiencing  homelessness, travelers) can have an impact on 
improving coverage among young adults
26
Criteria 1: Is the problem of public health importance?
WORK GROUP JUDGEMENTS
       | Minimal   Small    Moderate    Large Don’t know  Varies
EVIDENCE
–
–
–
HAVRIX and VAQTA are highly immunogenic when administered to children and adolescents 
• 97%–100% of persons aged 2–18 years had protective levels of antibody 1 month after 
receiving the first dose, and 100% had protective levels 1 month after the second dose, with 
high GMTs (Clemens 1995, Nalin 1995, McMahon Williams 1995, Asher 1999, Balcarek 1995, Horng 1993, Findor
1996, Sharapov 2012, Van Herck 2005)
• Anti-HAV has been shown to persist for at least 22 years in adults administered inactivated 
vaccine as children (aged 3-6 years) (Plumb 2017, Mosites 2018) 
Mathematical modelling based on persons vaccinated as adults predicted that seropositive anti-
HAV levels would persist in ≥95% vaccinees at year 30 and ≥90% at year 40 (Theeten 2015) 
Cellular immunity has been shown to promote HAV-specific cellular immunity similar to that 
induced by natural infection (Melgaco 2015)
Criteria 2: How substantial are the desirable anticipated 
effects? 
20
WORK GROUP JUDGEMENTS
Minimal     Small    Moderate     Large  Don’t know   |  Varies
 Additional Information:
–
–
–
Catch-up vaccination is a way to increase herd immunity and ensure the percentage of 
children/adolescents who miss vaccination as scheduled or who were born outside of the routine 
vaccination cohort are protected  
Since the implementation of risk-based vaccination in adults has been poor, catch-up vaccination 
will more rapidly increase the proportion of adults with risk factors who are protected 
HepA vaccination in childhood has demonstrated long-term protection
Criteria 2: How substantial are the desirable anticipated 
effects? 
20
WORK GROUP JUDGEMENTS
Minimal          | Small   Moderate  Large   Don’t know   Varies
EVIDENCE:
–
–
–
Rates of adverse events following HAVRIX, VAQTA and TWINRIX vaccination were similar to those 
seen with separately administered vaccines 
No unusual or unexpected safety patterns were observed in VAERS for any HepA vaccines 
(unpublished, CDC 2016)
Additional Information:
Limited data from studies conducted among adults indicate that simultaneous administration of 
hepatitis A vaccine with diphtheria, poliovirus (oral and inactivated), tetanus, typhoid (both oral 
and IM), cholera, Japanese encephalitis, rabies, or yellow fever vaccines does not decrease the 
immune response to either vaccine or increase the frequency of reported adverse events (Bienzle
2002, Jong 2002, Gil 1996)
29
Criteria 3: How substantial are the undesirable anticipated 
effects? 
Criteria 4: Do the desirable effects outweigh the undesirable 
effects?
WORK GROUP JUDGEMENTS
 Favors intervention          |  Favors comparison  Favors both  Favors neither  Unclear
EVIDENCE
–
–
–
–
HepA vaccination affords long-term protection against HAV infection 
Disease severity increases in older persons and persons who are immunocompromised, have chronic 
liver disease or other underlying health conditions
Over 20 years of safety monitoring have shown no known safety concerns  
Earlier HepA vaccination among healthy children/adolescents provides protection against HAV 
infection before persons develop increased risk for HAV infection or HAV-associated complications
30
Criteria 5: What is the overall certainty of this evidence 
for the critical outcomes?
WORK GROUP JUDGEMENTS
Effectiveness of the intervention
 No included  studies  |    Very low    Low   Moderate  High
WORK GROUP JUDGEMENTS
Safety of the intervention
 No included  studies  |   Very low    Low   Moderate  High
Additional Information
– GRADE was not used to evaluate the evidence
• HepA vaccine has been recommended for administration to children since 1996 
• HepA vaccine has been recommended for catch-up vaccination based on shared clinical 
decision-making since 2006 
• The efficacy and safety of HepA vaccines has been evaluated and well-documented 
• There are no known safety concerns with HepA vaccines 31
32
Criteria 6: Does the target population feel that the desirable 
effects are large relative to undesirable effects?
WORK GROUP JUDGEMENTS
 No    Probably No  Uncertain    Probably Yes    Yes |  Varies
EVIDENCE
–
–
Substantial catch-up implementation and acceptance despite a recommendation based on shared clinical 
decision-making
• In 2017, HepA coverage among adolescents aged 13-17 years nationally was 68.4% (≥2 doses), and 77.2% 
(1-dose), compared to 2008 coverage of 25.3% (≥2 doses) and 36.2% (1-dose); (Unpublished CDC, Nelson 
2018) 
Clear demand and preference for protection against hepatitis A 
• Although specific studies of desirability among older children or parents for hepatitis A vaccine have not 
been conducted, almost 80% of adolescents had initiated the hepatitis A vaccine series by 2017 (even 
without a recommendation for routine catch-up vaccination)
Additional Information
– The HepA vaccine adolescent 2-dose coverage is comparable or greater than other vaccines with a routine 
catch-up schedule which provides evidence of acceptability by the target population
WORK GROUP JUDGEMENTS
 Important uncertainty or variability     Possible important uncertainty or variability   
 Probably no important uncertainty or variability  no important uncertainty or variability |
 No known undesirable outcomes
EVIDENCE
– The high coverage rate, despite this recommendation being based on shared clinical decision making, provides 
strong and consistent evidence that most parents/patients believe that it is important (as important as some 
routinely recommended vaccines)
33
Criteria 7: Is there important uncertainty about or 
variability in how much people value the main outcomes?
Criteria 8: Is the intervention acceptable to key stakeholders?
WORK GROUP JUDGEMENTS
 No    Probably No  Uncertain    Probably Yes    Yes |  Varies
EVIDENCE
–
–
–
CDC currently does not have a routine catch up recommendation for children age 2-18 years, yet ~44% of 
states have introduced mandates for daycare or daycare plus school or school alone (Immunize.org)
• These states independently choose to achieve higher rates of vaccine coverage for children
• Increase in states with mandates from 28% in 2011 to 44% in 2018
HAV multistate outbreak response has led to growing level of awareness among all clinicians, states, and the 
general public about the value of a vaccine that provides lifelong protection 
https://www.cdc.gov/hepatitis/outbreaks/2017March-HepatitisA.htm
• Educational communications and two Health Alert Network advisories have been disseminated and 
accepted among these groups
Additional Information
The HepA adolescent 2-dose coverage is comparable or greater than other vaccines with a routine catch-up 
schedule which provides evidence of acceptability by key stakeholders population
34
WORK GROUP JUDGEMENTS
 No    Probably No    Uncertain    Probably Yes     Yes
EVIDENCE
–
–
–
–
–
Cost-effectiveness model used to assess nationwide routine hepatitis A vaccination was adapted to assess the 
cost-effectiveness of catch-up HepA vaccination among unvaccinated and partially vaccinated children 
compared with unvaccinated children (Hankin-Wei 2016) 
Findings: Over the lifetime of the cohort, catch-up vaccination would reduce the total number of infections 
relative to the baseline by 741 while increasing doses of vaccine by 556,989 
Across age-cohorts, the cost-effectiveness of catch-up vaccination was most favorable at age 12 years, due to 
splitting administration costs with other vaccines, resulting in an incremental cost-effectiveness ratio (ICER) of 
$189,000 per QALY gained
Catch-up was more cost-effective when it is assumed to replace more adult vaccination  
• Targeting children in late adolescence: higher probability of symptomatic disease among older children, 
less discounting of future costs of disease and less delay in averting adult vaccination costs
The impact of vaccination on the incremental cost-effectiveness ratio (ICER) was most sensitive to the 
discount rate (3%), followed by the rate of adult vaccination
35
Criteria 9: Is the intervention a reasonable and efficient 
allocation of resources?
WORK GROUP JUDGEMENTS
 No    Probably No    Uncertain    Probably Yes     Yes
Additional Information
–
–
–
–
–
Limitations: model output is based on hepatitis A incidence from 2008-2012; conclusions are strongly tied to 
factors such as vaccine uptake and disease transmission patterns which may change over time, altering future 
cost; model excluded herd immunity effects of vaccination
• The incremental costs of catch-up now would be more favorable, because adolescent vaccination 
coverage rates are much higher than when this study was conducted  
2009, 1 dose: 42%, 2-dose: 29.5% 
2017, 1 dose: 77.2%, 2-dose 68.5% 
• Higher HAV incidence overall today due to ongoing multistate outbreaks
2012, 0.5 cases/100,000 population 
2017, 1.0 case/100,000 population 
36
Criteria 9: Is the intervention a reasonable and efficient 
allocation of resources?
WORK GROUP JUDGEMENTS
 No    Probably No    Uncertain    Probably Yes     Yes
Additional Information
Cost Example: 
Targets: 80% completion, 90% initiation 
Assumptions: 
1) 2017 coverage rates apply to all (younger adolescents have higher coverage) 
2) 100% of 1-dose recipients complete series when calculating cost of 80% completion 
3) Assumed 50% of vaccination cost is at the private price and 50% at the CDC price
4) Vaccine cost:  $32.89 Private; $20.52 CDC
Adolescent population aged 12-17 years, 2017: 25,062,399
37
Criteria 9: Is the intervention a reasonable and efficient 
allocation of resources?
Coverage (using total 12-17 population and 
2017 coverage)
Additional 
1-dose vaccinees
Additional 
2-dose vaccinees Cost - Private (50%) Cost - CDC (50%)
90% 1 dose age 12-17 3,207,987 0 $52,755,347 $32,913,947 
80% 2 dose age 12-17 2,205,491 701,747 $59,349,766 $37,028,191 
HepA Vaccination Coverage 2017 To reach target
1 dose, age 13-17y 77.2% 12.8% need 1 dose to reach 90%
2 dose, age 13-17y 68.4% 8.8% need one more dose; 2.8% need two doses to reach 80%
Criteria 10: Is the intervention feasible to implement?
WORK GROUP JUDGEMENTS
 No    Probably No    Uncertain   Probably Yes    Yes   |   Varies
EVIDENCE
–
–
–
–
Of the 30 registries American Immunization Registry Association (AIRA) were able to query to test 
forecasting algorithms, 27 already routinely forecast hepatitis A vaccine as being due for an 18 year old 
who has never been vaccinated
• All 30 algorithms forecast the 2nd dose in any 18 year old who has had one dose 
• Therefore, 27 of 30 tested registries would not have to change to implement routine catch-up 
Additional Information
Routine HepA vaccine catch-up already exists in states with school mandates
In New York City, all children and adolescents not previously vaccinated should receive the two-dose 
hepatitis A vaccine series by their 19th birthday for lifetime protection (NYC Bureau of Health)
Opportunities to administer HepA vaccine to adolescents concurrently with vaccines protecting against 
other infections, such as HPV and meningitis
38
Criteria 10: Is the intervention feasible to implement?
WORK GROUP JUDGEMENTS
 No    Probably No    Uncertain   Probably Yes    Yes   |   Varies
Additional Information:
– A 2014 survey found that if ACIP made a recommendation for catch-up HepA
vaccination at health maintenance visits for all children 2 to 18 years of age, 96% of 
pediatricians and 79% of family medicine physicians reported it would be very feasible 
to routinely assess HepA vaccination status and vaccinate children/adolescents who 
were not fully vaccinated; an additional 4% and 19%, respectively, indicated it would 
be moderately feasible (Nelson 2017) 
• Since then, increased education and awareness among providers and the public due to the ongoing 
HAV outbreaks, have likely decreased barriers to vaccination 
39
Balance of consequences
WORK GROUP JUDGEMENTS





Undesirable consequences clearly outweigh desirable consequences
in most settings
Undesirable consequences probably outweigh desirable consequences
in most settings
The balance between desirable and undesirable consequences is closely    
balanced or uncertain
 Desirable consequences probably outweigh undesirable consequences
in most settings
Desirable consequences clearly outweigh undesirable consequences
in most settings
There is insufficient evidence to determine the balance of consequences
40
Is there sufficient information to move forward with a 
recommendation?
 Yes
 No
41
Policy Options for ACIP Consideration
 ACIP does not recommend the intervention
 ACIP recommends the intervention for individuals based on shared 
clinical decision-making 
 ACIP recommends the intervention
42
Proposed Routine Recommendations for Children
 ACIP recommends hepatitis A vaccination for all children aged 12-
23 months [Current]
 ACIP recommends that all children and adolescents aged 2 
through 18 years who have not previously received hepatitis A 
vaccine be vaccinated at any age (i.e., children and adolescents 
are recommended for catch-up vaccination) [Proposed]
43
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 Plumb ID, Bulkow LR, Bruce MG, Hennessy TW, Morris J, Rudolph K, Spradling P, Snowball M, McMahon BJ. Persistence of 
antibody to Hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska. J Viral Hepat. 2017 Jul;24(7):608-612. 
doi: 10.1111/jvh.12676. Epub 2017 Feb 2. PubMed PMID:28092416. 
 Sharapov UM, Bulkow LR, Negus SE, Spradling PR, Homan C, Drobeniuc J, Bruce M, Kamili S, Hu DJ, McMahon BJ. 
Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year 
follow-up. Hepatology. 2012 Aug;56(2):516-22. doi: 10.1002/hep.25687. Epub 2012 Jun 11. PubMed PMID:22371069.
 Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after 
vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based 
predictions. Vaccine. 2015 Oct 13;33(42):5723-5727. doi: 10.1016/j.vaccine.2015.07.008. Epub 2015 Jul 16. PubMed 
PMID:26190091.
 Widespread outbreaks of hepatitis A across the United States. https://www.cdc.gov/hepatitis/outbreaks/2017March-
HepatitisA.htm 45
Persons With HIV
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Proposed Recommendation for Persons With HIV (PWHIV)
 ACIP recommends that all persons with HIV aged ≥1 year be 
vaccinated with hepatitis A vaccine [Proposed]
47
Policy Question
Should routine two-dose* vaccination to prevent hepatitis A virus 
infection be given to HIV-positive persons?
*Or three-dose when combination vaccine is used
48
Population Adult HIV-positive persons regardless of another 
indication for vaccination
Intervention Routine two-dose hepatitis A vaccination
Comparison No routine two-dose hepatitis A vaccination
Outcomes of 
interest
 Hepatitis A Infection
 Mild Adverse Events
 Serious Adverse Events
Background: Persons With HIV 
 At the end of 2016, an estimated 1.1 million people aged 13 years and older had HIV 
infection in the United States1
 When PWHIV are co-infected with HAV infection, they experience higher HAV viral 
loads and a prolonged duration of hepatitis A viremia than persons without HIV 
infection2,3
– HAV infection has the potential to increase HIV viral loads and HIV transmission
 PWHIV respond to HepA vaccine with a seroconversion rate of 48.5%-93.9% 
following a 2-dose monovalent vaccine schedule, and factors associated with a 
protective antibody response in PWHIV include a CD4 cell count >200 cells/mm3 and 
a low HIV RNA viral load4,5
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1) CDC. HIV Surveillance Supplemental Report 2019;24(1).
2) Puoti, M., et al. Semin Liver Dis (2012) 32(02): 103-113.
3) Gallego, M., et al. Journal of the International Association of Physicians in AIDS Care, vol. 10, no. 1, Jan. 2011, pp. 40–42.
4) Weissman, S. , Feucht, C. and Moore, B. A. (2006), Journal of Viral Hepatitis, 13: 81-86. 
5) Mena, G et al. Human vaccines & immunotherapeutics vol. 11,11 (2015): 2582-98. 
Diagnoses of HIV Infection, by Age, 2017, U.S. and 6 
Dependent Areas
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 In 2017, the number of new HIV diagnoses in the U.S. and 6 dependent areas 
was 38,739
Age (Years) Number of Diagnoses of HIV Infection, 2017
13-14 25
15-19 1,723
20-24 6,416
25-29 7,755
30-34 5,678
35-39 4,365
40-44 3,032
45-49 3,006
50-54 2,729
55-59 1,918
60-64 1,108
65 and older 885
Diagnoses of HIV Infection by Transmission Category
 CDC classifies HIV diagnoses into transmission categories to which transmission 
may be attributed
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a Includes infections attributed to male-to-male sexual contact and injection drug use (men who reported both risk factors).
b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
c Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
Transmission 
Category
Adult and 
Adolescent 
Males
Adult and 
Adolescent 
Females
Total (%)
Male-to-male 
sexual contact 25,748 NA 25,748 (66.6)
Injection drug use 1,373 1,016 2,389 (6.2)
Male-to-male 
sexual contact and 
injection drug usea
1,252 NA 1,252 (3.2)
Heterosexual 
contactb 2,829 6,341 9,170 (23.7)
Otherc 37 44 81 (0.2)
 76% of ALL persons 
currently newly 
diagnosed with HIV 
have a risk factor for 
which HepA vaccine is 
already 
recommended 
(shown in red font)
What percentage of PWHIV do not have an 
existing risk factor for which HepA vaccine is 
recommended?
Risk Factors for which HepA Vaccination is 
Recommended Among PWHIV, MMP, 2016
*CV>.3, estimate is unstable
Denominator is all records containing a diagnosis dataset
Risk Factor Number Weighted Percent 95% CI
MSM in past 12 months 1202 32.5 (30.3 - 34.6)
Non-injection drug use 
in past 12 months
1156 28.7 (26.0 - 31.5)
Injection drug use in 
past 12 months
114 2.4 (1.7 - 3.2)
Homeless in past 12 
months
332 8.4 (7.3 - 9.5)
Chronic liver disease 601 15.0 (13.4 - 16.6)
Clotting factor disorder* 8 0.2* (0.05 - 0.3)
Any of the above 2313 59.9 (57.3 - 62.4)
None of the above 1529 40.1 (37.6 - 42.7)
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GRADE Summary
Evidence to Recommendation Framework
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HAV infection among PWHIV
 Among people with a diagnosis of HIV who received outpatient HIV medical care 
during 2014-2017, the prevalence of a diagnosis of hepatitis A recorded in the 
medical record at the primary HIV care site during a 2-year period was 0.48% (95% 
CI=0.26-0.70)
–
–
–
The  weighted frequency (population estimate) of hepatitis A infection was 4404 (+/- 1105) 
The population estimate of persons receiving HIV care was 917,942
This does not include undiagnosed hepatitis A infection and cases diagnosed elsewhere and not 
recorded in the medical record of the primary HIV care site
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HAV Outbreaks and PWHIV
 HIV co-infection outbreak data is available for a limited number of states:
–
–
–
–
–
Among 249 reported cases of HAV in Tennessee, 11 (4%) patients were PWHIV (September 20, 
2018)
Among 359 reported cases of HAV in Massachusetts, 14 (4%) were PWHIV (June 5, 2019)
Among 85 reported cases of HAV in Illinois, 7 (8.2%) were PWHIV (June 5, 2019)
 Clear excess HAV infection risk among PWHIV
U.S. population estimate of 327 million 
PWHIV are less than 0.34% of the general U.S. population
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https://www.census.gov/quickfacts/fact/table/US/PST045218
Brennan J, Moore K, Sizemore L, et al. MMWR Morb Mortal Wkly Rep 2019;68:328–329. 
http://www.dph.illinois.gov/hepatitisA (accessed 6/12/2019).
https://www.mass.gov/info-details/current-hepatitis-a-outbreak (accessed 6/12/2019)
ACIP Committee Questions from February 2019
 Is there value in knowing laboratory criteria before administering the 
vaccine? Should anti-HAV titers be checked periodically after vaccine 
administration? Will CD4 count thresholds be utilized for the 
recommendation of HepA vaccination among PWHIV?
 What are the costs of vaccinating PWHIV?
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Laboratory Postvaccination Testing
 Since response to vaccine might be reduced in PWHIV who are 
immunosuppressed (lower CD4 counts), postvaccination testing is proposed 
to be recommended for all PWHIV at least 1 month after vaccination
 Although patients with lower CD4 counts may respond less well to the 
vaccine, in order to avoid missed opportunities to immunize, immunization 
against hepatitis A should not be delayed until the CD4 count exceeds a 
particular threshold
 PWHIV who do not respond to vaccine should be considered susceptible to 
HAV infection and counseled about precautions to prevent HAV infection 
and the need to obtain IG post-exposure prophylaxis for any known or likely 
exposure to an HAV infected person
59
Costs of Vaccination – Adult Vaccination Price List
60
Vaccine Brandname/ Tradename NDC Packaging
CDC Cost/ 
Dose
Private Sector 
Cost/ Dose
Hepatitis A-
Adult [a]
Vaqta®
Merck
00006-
4096-02
00006-
4841-41
10 pack – 1 dose 
syringe
10 pack – 1 dose 
vial
$28.28
$26.29
$68.23
$68.23
Hepatitis A 
Adult [a]
Havrix®
GlaxoSmithKline 58160-0826-52
10 pack – 1 dose 
syringe $28.28 $67.55
Hepatitis A-
Hepatitis B 
Adult [b]
Twinrix®
GlaxoSmithKline
58160-
0815-52
10 pack – 1 dose 
syringe $56.76 $104.00
Footnotes
a. Vaccine cost includes $0.75 per dose Federal Excise Tax
b. Vaccine cost includes $1.50 per dose Federal Excise Tax
https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html
How much would it cost to vaccinate PWHIV? 
 A formal cost effectiveness analysis was not done for PWHIV as a risk group for 
HepA vaccination
 Consider ~400,000 PWHIV, potentially unvaccinated for HepA (assume 50% 
vaccine uptake)
–
–
–
–
–
200,000 X $68 = $13,600,000 (1-dose) 
200,000 X $136 = $27,200,000 (2-doses) 
Vaccine administration fees range from a few dollars up to twenty dollars (best available data)
 Other considerations:
Not all PWHIV will be vaccinated at the same time; cost would be spread out over time
Herd protection - vaccination in this high risk population would help disrupt outbreaks
 In an outbreak response the costs associated including health care expenses and 
deferred activities is substantial 61
Proposed Recommendation for Persons With HIV (PWHIV)
 ACIP recommends that all persons with HIV aged ≥1 year be 
vaccinated with hepatitis A vaccine [Proposed]
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Pregnancy - Update
63
Recommended Adult Immunization Schedule by Medical Condition 
and Other Indications, United States, 2019
64
Hepatitis A Virus Infection - Pregnancy and Infancy
 Review published data on hepatitis A during pregnancy1
–
–
–
Associated with gestational complications (e.g. preterm labor, placental 
abruption, premature rupture of membranes)2
Infants born to mothers with HAV infection are healthy (rare exceptions)
No increased risk of maternal or infant mortality after HepA vaccination in 
pregnancy
1Chaudhry SA, Koren G. Hepatitis A infection during pregnancy. Can Fam Physician 2015;61:963-964.
2Elinav E, Ben-Dov IZ, Shapira Y, Daudi N, Adler R, Shouval D, Ackerman Z. Acute hepatitis A infection in pregnancy is 
associated with high rates of gestational complications and preterm labor. Gastroenterology. 2006 Apr;130(4):1129-34 65
VAERS Study 2014 – HepA Vaccination in Pregnancy
 Searched VAERS for adverse event (AE) reports in pregnant women who received 
HepA or HepAB vaccine from Jan. 1, 1996 – April 5, 2013 
 VAERS received 139 reports of AEs in pregnant women; 7 (5.0%) were classified as 
serious; Sixty-five (46.8%) did not describe any AEs; no maternal or infant deaths 
were identified 
– No unusual clustering of birth defects were observed in this review
 Conclusion: This review of VAERS reports did not identify any concerning pattern 
of AEs in pregnant women or their infants following maternal HepA or HepAB
immunizations during pregnancy
Moro PL, Museru OI, Niu M, et al. Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women. 
Am J Obstet Gynecol 2014;210:561.e1-6. 66
Vaccine Safety Datalink (VSD) 
 Preliminary results of a large, ongoing retrospective cohort study in the Vaccine 
Safety Datalink (VSD) were presented to the work group
 Among pregnancies ending in live births, HepA vaccine was not associated with 
common maternal and infant adverse events, but a potential signal for small for 
gestational age (SGA) births was identified
– The observed effect size for SGA was an absolute difference of 4% (12.3 vs. 8.3%) 
• General US prevalence estimates for SGA are approximately 10%, and up to 
14% among women of Asian race (who comprised 30% of the vaccine 
exposed group in the study)
 The investigators and the work group considered that this SGA finding was likely 
due to unmeasured confounding, and unlikely to be clinically meaningful
 This study is expected to be published later this year
Unpublished; Vaccine Safety Datalink 67
Proposed Hepatitis A Vaccine Recommendation for 
Pregnant Women
 ACIP recommends that: 
–
–
Pregnant women who are identified as being at risk for HAV infection during 
pregnancy or for having a severe outcome from HAV infection (e.g., travelers, 
persons who use injection and non-injection drugs, persons who have 
occupational risk for infection, persons who anticipate close personal contact 
with an international adoptee, persons experiencing homelessness, persons with 
chronic liver disease, PWHIV) should be vaccinated during pregnancy if not 
previously vaccinated [Proposed]
Pregnant women who are not vaccinated against HAV infection during pregnancy 
should be counseled concerning other methods to prevent HAV infection 
[Proposed]
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Clotting Factor Disorders
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Clotting Factor Disorders –
Proposed Removal of Recommendation
 Persons who have clotting-factor disorders have been recommended to receive the 
HepA vaccination since 19961
 However, the risk of HAV infection has decreased over time, and the risk for viral 
transmission for persons with clotting factor disorders is considered the same as that for 
the general population2
–
–
–
In the U.S., >80% of persons with hemophilia are treated with recombinant clotting factor concentrates, which are 
sterilized (e.g., pasteurization, heat inactivation, filtration) enabling these factors to be safe2
Previously, some processes focused only on treatment with solvents/detergents which inactivated lipid-enveloped 
viruses (3), but not non-enveloped viruses, such as HAV, resulting in a risk for HAV infection4
Secondary virus reduction steps are now common2,5,6
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(1) Fiore AE, Wasley A, Bell BP. MMWR Recomm Rep 2006;55:1-23  (2) Klamroth, R. , Gröner, A. and Simon, T. L. (2014), Transfusion, 54: 1406-1417. 
(3) Tabor, E. (1999), Transfusion, 39: 1160-1168. (4) Mannucci PM, Gdovin S, Gringeri A, et al. Ann Intern Med 1994;120:1–7.
(5) GRÖNER, A. (2008), Haemophilia, 14: 54-71.     
(6) US Food and Drug Administration. Guide to inspections of viral clearance process for plasma derivatives. 2009. [cited 2013 Jan 25]. Available from: 
                            
https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB98137144.xhtml
1996 ACIP Hepatitis A Vaccine Recommendation - Background 
 Persons Who Have Clotting-Factor Disorders
–
–
–
During 1992–1993, several outbreaks of hepatitis A were reported in Europe 
among persons who had clotting-factor disorders who had been administered 
solvent detergent–treated factor VIII concentrates that presumably had been 
contaminated from plasma donors incubating HAV1
In the United States, data from one serologic study suggested that hemophilic 
patients may be at increased risk for HAV infection2
During 1995–1996, several patients who had clotting-factor disorders reportedly 
developed hepatitis A after having been administered solvent-detergent–treated 
factor VIII and factor IX concentrates3
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(1) Mannucci PM, Gdovin S, Gringeri A, et al. Ann Intern Med 1994;120:1–7.
(2) Mah MW, Royce RA, Rathouz PJ, et al. Vox Sang 1994;67(suppl 1): 21–2.
(3) CDC. MMWR 1996;45:29–32.
2006 ACIP Hepatitis A Vaccine Recommendations
 Persons with Clotting-Factor Disorders
–
–
(same as 1996) Susceptible persons who are administered clotting-factor 
concentrates, especially solvent-detergent–treated preparations, should receive 
HepA vaccine
(added) Changes in clotting factor preparation practices and donor screening 
have greatly reduced the risk for hepatitis A for recipients of clotting factors
72
Case Studies of Hepatitis A among Persons who Have 
Clotting Factor Disorders
 No case studies of hepatitis A infections among U.S. persons with 
clotting factor disorders were found in the literature in the last 20 
years 
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Soucie JM, Robertson BH, Bell BP, et al. Hepatitis A virus infections associated with clotting factor concentrate in the United States. 
Transfusion 1998;38:573-9.
Clotting Factor Disorders
 Work Group Considerations:  
–
–
–
–
–
–
–
Persons who have clotting-factor disorders has been a risk group for HepA vaccination 
since 1996
Risk of HAV has decreased over time, and persons with clotting factors are currently at 
an extremely low risk for infection with HAV
No case study reported for any person in the U.S. infected with HAV after exposure to 
clotting factor in 20 years (1)
Secondary virus reduction steps are now common instead of solvent-detergent treated
Many of the clotting factors now in use are recombinant factors
Source plasma is now screened for HAV (2)
No longer a specific risk of HAV infection associated with clotting factor disorders; 
therefore this group may be removed from consideration as part of a high risk 
population for whom HepA vaccination is specifically recommended
(1) Soucie JM, Robertson BH, Bell BP, et al. Transfusion 1998;38:573-9.
(2) Gröner, A. (2008). Haemophilia, 14: 54-71. 74
Proposed Recommendations
75
Proposed Routine Recommendations for Children
 ACIP recommends hepatitis A vaccination for all children aged 12-
23 months [Current]
 ACIP recommends that all children and adolescents aged 2 
through 18 years who have not previously received hepatitis A 
vaccine be vaccinated at any age (i.e., children and adolescents 
are recommended for catch-up vaccination) [Proposed] 
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Recommended Risk Groups for HepA Vaccination
Persons At Increased Risk for HAV Infection
–
–
–
–
–
–
–
–
–
Persons traveling to or working in countries that have high or intermediate endemicity of 
Infection. 
Men who have sex with men (MSM)
Persons who use injection or non-injection drugs
Persons who have occupational risk for infection
Persons who anticipate close contact with an international adoptee
Persons experiencing homelessness 
Persons with clotting factor disorders
Persons At Increased Risk For HAV Associated Complications
Persons with HIV [Vote 2]
Persons with chronic liver disease (update)
Any person wishing to obtain immunity
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Persons With HIV (PWHIV)
 ACIP recommends that all persons with HIV aged ≥1 year be vaccinated with 
hepatitis A vaccine [Proposed]
 Clinical guidance
–
–
–
–
Since response to vaccine might be reduced in PWHIV who are immunosuppressed, post-
vaccination testing is recommended for all PWHIV at least 1 month after vaccination
Although PWHIV with lower CD4 cell counts or percentages may have reduced response to the 
vaccine, in order to avoid missed opportunities to immunize, immunization against hepatitis A 
should not be delayed until the CD4 cell count exceeds a particular threshold 
PWHIV who do not respond to vaccine should be considered susceptible to HAV infection and 
counseled about precautions to prevent HAV infection and the need to obtain IG post-exposure 
prophylaxis for any known or likely exposure to HAV
PWHIV who received hepatitis A vaccine should be counseled that the vaccination against 
hepatitis A infection may not provide long term protection and they may need to obtain IG 
after a high risk HAV exposure (e.g., sexual or household contact) 
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Persons with Chronic Liver Disease  [Update]
 ACIP recommends that: 
– Persons with chronic liver disease (including, but not limited to, 
persons with hepatitis B virus infection, hepatitis C virus infection, 
cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune 
hepatitis, and an alanine aminotransferase [ALT] or aspartate 
aminotransferase [AST] level greater than twice the upper limit of 
normal) should be routinely immunized against hepatitis A. 
[Proposed]
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Proposed Hepatitis A Vaccine Recommendation for 
Pregnant Women
 ACIP recommends that: 
–
–
Pregnant women who are identified as being at risk for HAV infection during 
pregnancy or for having a severe outcome from HAV infection (e.g., travelers, 
persons who use injection and non-injection drugs, persons who have 
occupational risk for infection, persons who anticipate close personal contact 
with an international adoptee, persons experiencing homelessness, persons 
with chronic liver disease, PWHIV) should be vaccinated during pregnancy if 
not previously vaccinated [Proposed]
Pregnant women who are not vaccinated against HAV infection during 
pregnancy should be counseled concerning other methods to prevent HAV 
infection [Proposed]
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Implementation Strategies
 Settings Providing Services to Adults (NEW)
–
–
–
–
Settings in which a high proportion of persons have risk factors for HAV infection (e.g., health 
care settings targeting services to people who use injection or non-injection drugs, group 
homes and nonresidential day care facilities for developmentally disabled persons).  A health 
care provider (HCP) may assume that unvaccinated adults age ≥19 years are at risk for HAV 
infection and offer hepatitis A vaccination without individual risk-factor screening if they have 
not previously completed vaccination 
Hepatitis A vaccination may be offered in outreach and other settings in which services are 
provided to persons at risk for HAV infection (e.g., homeless shelters, syringe service programs) 
HCP should consider implementing standing orders to identify adults recommended for 
hepatitis A vaccination and administer vaccination as part of routine services
Vaccination of staff should be considered in facilities where hygiene is difficult to maintain 
(e.g., group homes for developmentally disabled)
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Recommendations for Hepatitis A Vaccination During an 
Outbreak (Update)
 ACIP recommends that:
–
–
All unvaccinated children aged ≥1 year and adults age ≥19 years who are at risk for 
HAV infection (e.g., persons who use injection or non-injection drugs, persons 
experiencing homelessness) should receive one dose of hepatitis A vaccine during a 
hepatitis A outbreak [Proposed]
In the event of a community outbreak propagated by person-to-person transmission, 
public health officials should consider recommending administration of pre-exposure 
hepatitis A vaccination in close congregate settings providing services to high risk 
persons in the vicinity of the outbreak (e.g,. persons incarcerated in correctional 
facilities, health care settings targeting services to people who use injection or non-
injection drugs, homeless shelters, syringe service programs) due to the risk of an 
outbreak in these settings and increased risk of HAV infection among persons in these 
settings [Proposed]
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Prevaccination Serologic Testing (Update)
–
–
–
–
–
Prevaccination serologic testing for hepatitis A immunity prior to vaccination is not 
recommended, but may be considered in specific settings as a way to reduce costs 
by not vaccinating persons who are already immune 
Prevaccination serologic testing should not be a barrier to vaccination of susceptible 
persons, especially in populations that are difficult to access 
If prevaccination serologic testing is performed, commercially available tests for 
total anti-HAV or IgG anti-HAV should be used
Antibody production in response to HAV infection results in lifelong immunity to 
hepatitis A and, presumably, to HAV infection 
Prevaccination serologic testing of children is not indicated because of their expected 
low prevalence of infection 
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Prevaccination Serologic Testing (Update)
–
–
–
–
Persons for whom prevaccination testing will likely be most cost-effective include 
adults who were either born in or lived for extensive periods in geographic areas that 
have a high or intermediate endemicity of HAV; and adults in certain population 
groups; American Indians, Alaska Natives, and Hispanics
In populations that are expected to have high rates of previous HAV infection, 
vaccination history should be obtained where feasible prior to testing or vaccination
Vaccinations should not be postponed if vaccination history cannot be obtained, if 
records are unavailable or if prevaccination testing is not feasible 
Vaccination of a person who is immune because of previous infection does not 
increase the risk for adverse events from vaccination
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Postvaccination Serologic Testing (Update)
– Testing for the presence of anti-HAV antibody after vaccination is 
recommended for the persons whose subsequent clinical management 
depends on knowledge of their immune status:  PWHIV, and other 
immunocompromised persons (e.g., hematopoietic stem-cell transplant 
recipients, persons receiving chemotherapy) 
– Testing should be performed at least one month after administration of the 
final dose of the vaccine series with total anti-HAV or IgG anti-HAV assays  
– Postvaccination testing is not indicated for other persons because of the high 
rate of hepatitis A vaccine response among children and adults 
– Persons who do not respond immunogenically to vaccination should be 
considered susceptible to HAV infection and counseled about precautions to 
prevent HAV infection and the need to obtain IG post-exposure prophylaxis for 
any known or likely exposure to a HAV infection 85
Revaccination  (New)
–
–
–
Revaccination (i.e., booster dose, challenge dose, or revaccination with a 
complete series) is not generally recommended for persons with a normal 
immune status who were vaccinated as infants, children or adults (Theeten
2015, Spradling 2016, Mosites 2018) 
Anti-HAV long-term persistence studies do not indicate a need for additional 
hepatitis A vaccine doses beyond the 2-dose primary vaccine series or 3-dose 
series if combination Hepatitis A-Hepatitis B vaccine was administered
For other immunocompromised persons (e.g., PWHIV, hematopoietic stem-cell 
transplant recipients, persons receiving chemotherapy), the ACIP has no 
specific guidance because limited data are available to determine the need for 
booster doses or revaccination with a complete series 
86
Other Guidance
 Interrupted Schedules and Minimum Dosing Intervals
 Other Immunization Management Issues and Considerations
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Proposed VOTE #1
 ACIP recommends that all children and adolescents aged 2 through 18 years who 
have not previously received hepatitis A vaccine be vaccinated at any age (i.e., 
children and adolescents are recommended for catch-up vaccination) 
Proposed VOTE #2
 ACIP recommends that all persons with HIV aged ≥1 year be vaccinated with 
hepatitis A vaccine
Proposed VOTE #3
 ACIP affirms the updated statement “Prevention of Hepatitis A Virus Infection in 
the United States: Recommendations of the Advisory Committee on 
Immunization Practices”
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For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for 
Disease Control and Prevention.
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